Pierrick G J Fournier
Overview
Explore the profile of Pierrick G J Fournier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gonzalez C, Venegas G, Fournier P, Chavez-Hernandez J, Camacho-Lopez S, Flores-Castaneda M, et al.
Environ Pollut
. 2025 Feb;
372:125875.
PMID: 39984018
Microplastic ubiquity has been demonstrated in several studies. They are polluting the environment, as well as food and water for human consumption, where the most significant concern has arisen over...
2.
Acosta Montano P, Olvera Felix E, Castro Flores V, Hernandez Garcia A, Cadena-Nava R, Galindo Hernandez O, et al.
Biology (Basel)
. 2025 Jan;
13(12.
PMID: 39765733
Liver metastases frequently occur in pancreatic and colorectal cancer. Their development is promoted by tumor-derived exosomes with the integrin αβ on their membrane. This integrin directs exosomes to the liver,...
3.
Calvert R, Fleet J, Fournier P, Juarez P, Burcham G, Haverkamp J, et al.
Immunohorizons
. 2022 Dec;
6(12):790-806.
PMID: 36480485
Owing to ease of access and high yield, most murine myeloid-derived suppressor cell (MDSC) knowledge comes from the study of spleen-derived MDSCs rather than those isolated from the tumor. Although...
4.
Arellano D, Juarez P, Verdugo-Meza A, Almeida-Luna P, Corral-Avila J, Drescher F, et al.
J Bone Miner Res
. 2022 May;
37(8):1446-1463.
PMID: 35635377
Immunotherapies use components of the immune system, such as T cells, to fight cancer cells, and are changing cancer treatment, causing durable responses in some patients. Bone metastases are a...
5.
Mendoza-Reinoso V, McCauley L, Fournier P
Cancers (Basel)
. 2020 Apr;
12(4).
PMID: 32326073
Bone is a common site for metastases with a local microenvironment that is highly conducive for tumor establishment and growth. The bone marrow is replete with myeloid and lymphoid linage...
6.
Nunez-Rivera A, Fournier P, Arellano D, Rodriguez-Hernandez A, Vazquez-Duhalt R, Cadena-Nava R
Beilstein J Nanotechnol
. 2020 Mar;
11:372-382.
PMID: 32175217
There is an increasing interest in the use of plant viruses as vehicles for anti-cancer therapy. In particular, the plant virus brome mosaic virus (BMV) and cowpea chlorotic mottle virus...
7.
Millan-Gomez D, Duenas S, Munoz P, Camacho-Villegas T, Elosua C, Cabanillas-Bernal O, et al.
Oncotarget
. 2018 Jul;
9(46):28016-28029.
PMID: 29963259
The stability, binding, and tissue penetration of variable new-antigen receptor (VNAR) single-domain antibodies have been tested as part of an investigation into their ability to serve as novel therapeutics. V13...
8.
Jain A, Fournier P, Mendoza-Lavaniegos V, Sengar P, Guerra-Olvera F, Iniguez E, et al.
J Nanobiotechnology
. 2018 Mar;
16(1):26.
PMID: 29566719
Background: Breast cancer is the second leading cause of cancer death among women and represents 14% of death in women around the world. The standard diagnosis method for breast tumor...
9.
Sengar P, Juarez P, Verdugo-Meza A, Arellano D, Jain A, Chauhan K, et al.
J Nanobiotechnology
. 2018 Feb;
16(1):19.
PMID: 29482561
Background: Photodynamic therapy is a promising cancer therapy modality but its application for deep-seated tumor is mainly hindered by the shallow penetration of visible light. X-ray-mediated photodynamic therapy (PDT) has...
10.
Juarez P, Fournier P, Mohammad K, McKenna R, Davis H, Peng X, et al.
Oncotarget
. 2017 Nov;
8(49):86447-86462.
PMID: 29156807
More efficient therapies that target multiple molecular mechanisms are needed for the treatment of incurable bone metastases. Halofuginone is a plant alkaloid-derivative with antiangiogenic and antiproliferative effects. Here we demonstrate...